The company expects contractual fill-finish demand from its largest customer to double beginning in 2027 and grow by more than 200% in 2028, compared to 2026.
Additional federal funding will support commercial-scale development of seven essential active pharmaceutical ingredients using the company’s modular continuous biomanufacturing platform.
